Earnings ·
Reports Q3 net income of $3M and raises full-year adjusted EBITDA guidance to $428-438M
ENOVEnovis Corp
Enovis reported third-quarter net sales of $559 million, a 2% increase on a reported basis and 5% organic growth. Net income was $3 million, or $0.02 per share, while adjusted EBITDA reached $104 million with an 18.5% margin. The company raised its full-year 2026 adjusted EBITDA guidance to $428-438 million and increased adjusted EPS expectations to $3.58-$3.79 from the previous range of $3.52-$3.73. Revenue guidance was narrowed to $2.32-2.35 billion, reflecting 5% organic growth. Additionally, the Board approved a new $200 million share repurchase authorization replacing the existing $100 million program. Enovis is a global medical technology innovator developing solutions for reconstructive surgery and prevention & recovery.